<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04107207</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001101</org_study_id>
    <nct_id>NCT04107207</nct_id>
  </id_info>
  <brief_title>Evaluating the Effects of Kombucha as a Hyperglycemic Therapeutic Agent Within Diabetic Human Subjects</brief_title>
  <official_title>Pilot Study to Evaluate Effects of Kombucha as a Hyperglycemic Therapeutic Agent Within Diabetic Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study's primary objective is to determine the ability of Kombucha to impact blood sugar&#xD;
      levels in patients with diabetes mellitus type II. The secondary objective is to determine&#xD;
      the ability of Kombucha to impact blood pressure, and quality of life measures as measured by&#xD;
      uniform questionnaire that includes: gut health, colds, infections, headaches, sleep, anxiety&#xD;
      (GAD2), depression (PHQ2), skin health.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 11, 2019</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double blind crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Sugar Levels</measure>
    <time_frame>10 weeks</time_frame>
    <description>outcome measure: mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut health</measure>
    <time_frame>10 weeks</time_frame>
    <description>Worst ever | worse than usual | average | better than usual | best ever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anxiety</measure>
    <time_frame>10 weeks</time_frame>
    <description>How often have you been bothered by the following problems? 6.1. Feeling nervous, anxious or on edge Not at all | Several days | More than half the days | Nearly every day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>depression</measure>
    <time_frame>10 weeks</time_frame>
    <description>How often have you been bothered by the following problems? 6.3. Little interest or pleasure in doing things Not at all | Several days | More than half the days | Nearly every day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin health</measure>
    <time_frame>10 weeks</time_frame>
    <description>4.1. How would you rate your overall skin health? Worst ever | worse than usual | average | better than usual | best ever 5. How often do you experience skin problems such as dry skin, eczema, rashes, or acne? Not at all | Several days | More than half the days | Nearly every day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vulvovaginal health</measure>
    <time_frame>10 weeks</time_frame>
    <description>9.1. How would you rate your overall vulvovaginal health? Worst ever | worse than usual | average | better than usual | best ever</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Kombucha Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Either ginger kombucha or placebo ginger water will be given to subjects for weeks 1-4 and then the reciprocal beverage for weeks 6-10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Intervention</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Either ginger kombucha or placebo ginger water will be given to subjects for weeks 1-4 and then the reciprocal beverage for weeks 6-10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ginger Kombucha</intervention_name>
    <description>Craft Ginger Kombucha, a fermented black tea</description>
    <arm_group_label>Kombucha Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ginger Water</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. S/he is above the age of 18&#xD;
&#xD;
          2. S/he has the ability to read, speak and write English&#xD;
&#xD;
          3. S/he has telephone access&#xD;
&#xD;
          4. S/he is diabetic and willing to check blood sugar levels every day&#xD;
&#xD;
          5. Hb A1c &gt;7%&#xD;
&#xD;
          6. Possesses a glucometer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy to kombucha ingredients&#xD;
&#xD;
          2. Drinks kombucha regularly (&gt;3time per week)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Georgetown University MedStar Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 1, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

